Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPARγ and PGC1α

Figure 6

PPARγ inhibitor (T0070907) reversed the protective effects of NOB against chronic heart failure after MI. (a) The survival curve showed that the mortality rate of the PPARγ inhibitor group was significantly higher than that of the NOB intervention group. The numbers of mice for the sham+vehicle, MI+vehicle, MI+NOB, and MI+NOB+PPARγ inhibitor were 8, 12, 10, and 12 at the beginning of the experiment, whereas after 3 weeks, the numbers were 8, 6, 7, and 6, respectively. Six mice were sacrificed in the MI+vehicle and MI+NOB+PPARγ inhibitor group, and four were sacrificed in the MI+NOB group. The survival rates for each group were 100%, 50%, 70%, and 50%. (b) Representative echocardiography images for all four groups (, 6, 7, and 6). (c) Parameters reflecting cardiac function showed reduced LVEF and LVFS and dilated LVIDd and LVIDs following PPARγ inhibitor administration, revealing worsened cardiac function after PPARγ inhibitor injection (, 6, 7, and 6). (d) The heart weight/body weight ratio increased in the inhibitor group (, 6, 7, and 6). Data are presented as . ; . PPARγ: peroxisome proliferator-activated receptor gamma; NOB: nobiletin; MI: myocardial infarction; LVEF: left ventricular ejection fraction; LVFS: left ventricular fractional shortening; LVIDd: left ventricular internal diameter at end diastole; LVIDs: left ventricular internal diameter at end systole.

(a)

(b)

(c)

(d)